Chris Feierabend
- Molecular Biology
- Oncology top 10%
- Pulmonary and Respiratory Medicine
- Cancer Research
- Biomedical Engineering
- Co-authors
- Dona AlbertiGeorge WildingR Z ArzoomanianK D TutschHoward H. BaileyRhoda ArzoomanianKendra D. TutschMarcia Pomplun
- Topics
- Cancer Treatment and Pharmacology (15 papers)Colorectal Cancer Treatments and Studies (5 papers)Cancer therapeutics and mechanisms (4 papers)
- Cited by
- OncologyBiochemistryCancer Research
- Journals
- Journal of Clinical OncologyJNCI Journal of the National Cancer InstituteInternational Journal of Radiation Oncology*Biology*Physics
- Partner nations
- United StatesSpainGermany
In The Last Decade
Chris Feierabend
27 papers receiving 792 citations
Peers
Comparison fields: 5 of 80
- Molecular Biology 375
- Oncology 364
- Pulmonary and Respiratory Medicine 129
- Cancer Research 111
- Biomedical Engineering 60
Countries citing papers authored by Chris Feierabend
This map shows the geographic impact of Chris Feierabend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Feierabend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Feierabend more than expected).
Fields of papers citing papers by Chris Feierabend
This network shows the impact of papers produced by Chris Feierabend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Feierabend. The network helps show where Chris Feierabend may publish in the future.
Co-authorship network of co-authors of Chris Feierabend
This figure shows the co-authorship network connecting the top 25 collaborators of Chris Feierabend. A scholar is included among the top collaborators of Chris Feierabend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Feierabend. Chris Feierabend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 6 | |
| 2 | 2 | |
| 3 | 11 | |
| 4 | 25 | |
| 5 | 21 | |
| 6 | 3 | |
| 7 | 100 | |
| 8 | 2 | |
| 9 | Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. | 2 |
| 10 | 16 | |
| 11 | 10 | |
| 12 | 5 | |
| 13 | 33 | |
| 14 | 5 | |
| 15 | 5 | |
| 16 | 44 | |
| 17 | 139 | |
| 18 | 3 | |
| 19 | 111 | |
| 20 | 46 |
About Chris Feierabend
Chris Feierabend is a scholar working on Oncology, Biochemistry and Reproductive Medicine, having authored 27 papers that have together received 820 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Oncology (364 citations), Biochemistry (58 citations) and Cancer Research (111 citations). Chris Feierabend has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Dona Alberti, George Wilding, R Z Arzoomanian, K D Tutsch, Howard H. Bailey, Rhoda Arzoomanian, Kendra D. Tutsch, Marcia Pomplun, Gregory H. Ripple and Rebecca Marnocha. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.